{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:49:55Z","timestamp":1780472995237,"version":"3.54.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Guideline-directed medical therapy (GDMT) for heart failure (HF) with reduced ejection fraction (HFrEF) has been demonstrated to significantly reduce morbidity and mortality. However, many patients, especially those with advanced HFrEF, are unable to tolerate optimal GDMT due to hypotension. Cardiac contractility modulation (CCM) is a novel therapeutic approach that enhances myocardial contractility and reverses cardiac remodeling, thereby improving cardiac function and quality of life in patients with HFrEF. However, whether CCM can bridge the hemodynamic vulnerability phase to facilitate GDMT optimization and improve patient prognosis remains unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 56-year-old man with dilated cardiomyopathy and HFrEF (<jats:italic>N<\/jats:italic>YHA functional class III) had recurrent hospitalizations for HF over the past 4 years. Due to hypotension (systolic blood pressure \u226490\u2005mmHg), the patient was unable to tolerate full-dose GDMT, with sacubitril-valsartan limited to 25\u2005mg twice daily, metoprolol succinate to 23.75\u2005mg once daily, and spironolactone to 20\u2005mg once daily. After a comprehensive evaluation, a CCM device was implanted as the most effective and evidence-based option. Postoperatively, the patient's blood pressure gradually improved, allowing initiation of the four major therapeutic drug classes, which were uptitrated to the maximum tolerated doses. With regular follow-up for 12 months, the patient showed dramatic improvements in exercise capacity and quality of life. More surprisingly, there was significant improvement in cardiac structural and functional remodeling. Echocardiography revealed that left atrioventricular dimensions returned to normal, left ventricular ejection fraction (LVEF) increased from 15% to 48%, and left ventricular global longitudinal strain (GLS) improved from \u22123.3% to \u221216.2%. NT-proBNP levels also decreased from 6,553\u2005pg\/ml to within the normal range.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case suggests that CCM may serve as a promising strategy to address the issue of poor GDMT tolerance due to hypotension, thereby facilitating GDMT optimization and improving cardiac remodeling patients with HFrEF.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2025.1577680","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T05:22:04Z","timestamp":1749187324000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Cardiac contractility modulation to enhance optimized medical therapy and improve cardiac remodeling in advanced heart failure: a case report"],"prefix":"10.3389","volume":"12","author":[{"given":"Lina","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/ejhf.3214","article-title":"Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. A survey of the heart failure association of the ESC and the ESC council for cardiology practice","volume":"26","author":"Savarese","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"B2","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1046\/j.1540-8167.2004.03580.x","article-title":"First human chronic experience with cardiac contractility modulation by nonexcitatory electrical currents for treating systolic heart failure: mid-term safety and efficacy results from a multicenter study","volume":"15","author":"Pappone","year":"2004","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.jacc.2014.01.051","article-title":"The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions","volume":"63","author":"Ambrosy","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/ehf2.12539","article-title":"Digoxin is associated with worse outcomes in patients with heart failure with reduced ejection fraction","volume":"7","author":"Zhou","year":"2020","journal-title":"ESC Heart Fail"},{"key":"B5","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.ijcard.2016.07.111","article-title":"Use of digoxin and risk of death or readmission for heart failure and sinus rhythm: a nationwide propensity score matched study","volume":"221","author":"Madelaire","year":"2016","journal-title":"Int J Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.ejheart.2005.05.001","article-title":"Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure","volume":"7","author":"Moertl","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"B7","doi-asserted-by":"publisher","first-page":"24097","DOI":"10.1038\/s41598-021-03317-5","article-title":"The effect of levosimendan on right ventricular function in patients with heart dysfunction: a systematic review and meta-analysis","volume":"11","author":"Hu","year":"2021","journal-title":"Sci Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jchf.2020.01.014","article-title":"Advanced heart failure: epidemiology, diagnosis, and therapeutic approaches","volume":"8","author":"Truby","year":"2020","journal-title":"JACC Heart Fail"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.jcmg.2009.07.011","article-title":"Impact of cardiac contractility modulation on left ventricular global and regional function and remodeling","volume":"2","author":"Yu","year":"2009","journal-title":"JACC Cardiovasc Imaging"},{"key":"B12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ehj.2004.02.027","article-title":"Chronic electrical stimulation during the absolute refractory period of the myocardium improves severe heart failure","volume":"25","author":"Stix","year":"2004","journal-title":"Eur Heart J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/eurheartj\/ehn020","article-title":"Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure","volume":"29","author":"Borggrefe","year":"2008","journal-title":"Eur Heart J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ahj.2010.10.025","article-title":"A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure","volume":"161","author":"Kadish","year":"2011","journal-title":"Am Heart J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.jchf.2018.04.010","article-title":"A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation","volume":"6","author":"Abraham","year":"2018","journal-title":"JACC Heart Fail"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/ejhf.1374","article-title":"Cardiac contractility modulation improves long-term survival and hospitalizations in heart failure with reduced ejection fraction","volume":"21","author":"Anker","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/ejhf.2202","article-title":"Long-term clinical experience with cardiac contractility modulation therapy delivered by the optimizer smart system","volume":"23","author":"Kuschyk","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/ehf2.14344","article-title":"Dramatic disease regression in a case of HFrEF with end-stage renal failure treated with sacubitril\/valsartan and SGLT2i","volume":"10","author":"Mapelli","year":"2023","journal-title":"ESC Heart Fail"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1362760","DOI":"10.3389\/fcvm.2024.1362760","article-title":"Editorial: cardiac reverse remodeling after novel heart failure therapies","volume":"11","author":"Mapelli","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1528743","DOI":"10.3389\/fcvm.2024.1528743","article-title":"Editorial: cardiac reverse remodeling after novel heart failure therapies-volume II","volume":"11","author":"Basile","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1542870","DOI":"10.3389\/fcvm.2025.1542870","article-title":"Dapagliflozin effects on exercise, cardiac remodeling, biomarkers, and renal and pulmonary function in heart failure patients: not as good as expected?","volume":"12","author":"Mapelli","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00228-023-03527-y","article-title":"Effects of sacubitril\/valsartan on exercise capacity: a prognostic improvement that starts during uptitration","volume":"79","author":"Mapelli","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ejhf.3081","article-title":"Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: an analysis from the HELP-HF registry","volume":"26","author":"Tomasoni","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.jchf.2023.07.002","article-title":"Device interventions for heart failure","volume":"11","author":"Salah","year":"2023","journal-title":"JACC Heart Fail"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/j.jacc.2006.10.082","article-title":"Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure","volume":"49","author":"Imai","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1016\/j.jacc.2005.05.093","article-title":"Electrical signals applied during the absolute refractory period: an investigational treatment for advanced heart failure in patients with normal QRS duration","volume":"46","author":"Lawo","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1054\/jcaf.2003.8","article-title":"Cardiac contractility modulation with nonexcitatory electric signals improves left ventricular function in dogs with chronic heart failure","volume":"9","author":"Morita","year":"2003","journal-title":"J Card Fail"},{"key":"B28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.cardfail.2006.11.004","article-title":"Enhanced inotropic state of the failing left ventricle by cardiac contractility modulation electrical signals is not associated with increased myocardial oxygen consumption","volume":"13","author":"Butter","year":"2007","journal-title":"J Card Fail"},{"key":"B29","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00392-017-1135-9","article-title":"Clinical effects of long-term cardiac contractility modulation (CCM) in subjects with heart failure caused by left ventricular systolic dysfunction","volume":"106","author":"M\u00fcller","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ehf2.14966","article-title":"The chronic heart failure evolutions: different fates and routes","volume":"12","author":"Agostoni","year":"2025","journal-title":"ESC Heart Fail"},{"key":"B31","doi-asserted-by":"publisher","first-page":"C319","DOI":"10.1093\/eurheartjsupp\/suad057","article-title":"Cardiopulmonary exercise testing and heart failure: a tale born from oxygen uptake","volume":"25","author":"Mapelli","year":"2023","journal-title":"Eur Heart J Suppl"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1577680\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T05:22:06Z","timestamp":1749187326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1577680\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":31,"alternative-id":["10.3389\/fcvm.2025.1577680"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1577680","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"article-number":"1577680"}}